ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

RA Guidelines Emphasize Costs and Shared Decision Making

RA Guidelines Emphasize Costs and Shared Decision Making

  • (©EdwardOlive/Shutterstock.com)
    (©EdwardOlive/Shutterstock.com)
  • (©EdwardOlive/Shutterstock.com)
    (©EdwardOlive/Shutterstock.com)
  • (©EdwardOlive/Shutterstock.com)
    (©EdwardOlive/Shutterstock.com)
  • (©EdwardOlive/Shutterstock.com)
    (©EdwardOlive/Shutterstock.com)
  • (©EdwardOlive/Shutterstock.com)
    (©EdwardOlive/Shutterstock.com)
  • (©EdwardOlive/Shutterstock.com)
    (©EdwardOlive/Shutterstock.com)
  • (©EdwardOlive/Shutterstock.com)
    (©EdwardOlive/Shutterstock.com)
  • (©EdwardOlive/Shutterstock.com)
    (©EdwardOlive/Shutterstock.com)
  • (©EdwardOlive/Shutterstock.com)
    (©EdwardOlive/Shutterstock.com)
  • (©EdwardOlive/Shutterstock.com)
    (©EdwardOlive/Shutterstock.com)
  • (©EdwardOlive/Shutterstock.com)
    (©EdwardOlive/Shutterstock.com)
  • (©EdwardOlive/Shutterstock.com)
    (©EdwardOlive/Shutterstock.com)
  • (©EdwardOlive/Shutterstock.com)
    (©EdwardOlive/Shutterstock.com)
  • (©EdwardOlive/Shutterstock.com)
    (©EdwardOlive/Shutterstock.com)
  • (©EdwardOlive/Shutterstock.com)
    (©EdwardOlive/Shutterstock.com)
  • (©EdwardOlive/Shutterstock.com)
    (©EdwardOlive/Shutterstock.com)
  • (©EdwardOlive/Shutterstock.com)
    (©EdwardOlive/Shutterstock.com)
The European League Against Rheumatism (EULAR) has updated its treatment recommendations for rheumatoid arthritis to reflect new evidence and, for the first time, it considers drug costs. The European League Against Rheumatism (EULAR) has updated its treatment recommendations for rheumatoid arthritis to reflect new evidence and, for the first time, it considers drug costs.
 
The updated guidelines are based on three systematic literature reviews leading to four overarching principles and 12 recommendations.
 
The recommendations address conventional synthetic DMARDs, which include methotrexate, leflunomide and sulfasalazine; glucocorticoid use; biologic DMARDs, which include TNF-inhibitors, such as adalimumab, certolizumab pegol, etanercept, golimumab and infliximab; biosimilar DMARDs; targeted synthetic DMARDs, such as Jak inhibitors tofacitinib and baricitinib; and, abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab.
 
“These recommendations intend to inform rheumatologists, patients, national rheumatology societies, hospital officials, social security agencies and regulators about EULAR's most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies,” EULAR writes in the March 17 issue of Annals of the Rheumatic Diseases.
 
In this slideshow, we summarize the new recommendations.
 
References: 

Josef S Smolen, Robert Landewe, Johannes Bijlsma, et al. “EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update,” Annals of the Rheumatic Diseases. 2017;0:1–18. doi:10.1136/annrheumdis-2016-210715

Comments

Too superficial note.There should be guide line deinitely how primary care physician should msnsge it before surgical management or immunological drugs in simplest form.Rheumatologist are very rae speccimen. JRB

Jati @

Add new comment

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.